NASDAQ:JANX Janux Therapeutics Q4 2024 Earnings Report $25.76 -0.42 (-1.60%) Closing price 04:00 PM EasternExtended Trading$25.76 0.00 (0.00%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Janux Therapeutics EPS ResultsActual EPS-$0.36Consensus EPS -$0.49Beat/MissBeat by +$0.13One Year Ago EPSN/AJanux Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AJanux Therapeutics Announcement DetailsQuarterQ4 2024Date2/27/2025TimeAfter Market ClosesConference Call DateThursday, February 27, 2025Conference Call Time4:00PM ETUpcoming EarningsJanux Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Janux Therapeutics Earnings HeadlinesJanux Therapeutics (NASDAQ:JANX) Now Covered by Raymond James FinancialJuly 14 at 2:47 AM | americanbankingnews.comRaymond James Initiates Coverage of Janux Therapeutics (JANX) with Outperform RecommendationJuly 12 at 2:25 AM | msn.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 15 at 2:00 AM | Crypto 101 Media (Ad)Janux Therapeutics Inc Ordinary Shares JANX - MorningstarJune 27, 2025 | morningstar.comMJonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price TargetJune 24, 2025 | msn.comJanux Therapeutics Becomes Oversold (JANX)June 20, 2025 | nasdaq.comSee More Janux Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Janux Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Janux Therapeutics and other key companies, straight to your email. Email Address About Janux TherapeuticsJanux Therapeutics (NASDAQ:JANX) is a clinical-stage immuno-oncology company headquartered in Cambridge, Massachusetts. Founded in 2021 by Flagship Pioneering, the company focuses on developing novel T-cell receptor (TCR) therapies to treat solid tumors. Janux has built an integrated research and development infrastructure that spans early discovery through clinical evaluation, emphasizing precision targeting of cancer antigens with engineered cell-therapy products. At the core of Janux’s approach is its proprietary RAMP (Receptor Activation through Membrane Proximal signaling) platform, which aims to enhance TCR signaling strength, specificity, and safety. Leveraging advanced protein engineering, cell-culture technologies, and in vivo modeling, the company advances a pipeline of TCR-T candidates directed against well-characterized tumor antigens such as MAGEA4 and MAGEA10. Preclinical studies conducted at its Cambridge facility have demonstrated promising anti-tumor activity, supporting the initiation of early-phase clinical trials in multiple solid tumor indications. Janux conducts its clinical programs across the United States and Europe through collaborations with leading cancer research centers and academic institutions. The company is led by President and Chief Executive Officer Christina Vernon, Ph.D., who brings more than 20 years of experience in oncology drug development. Janux’s executive team includes seasoned experts in cell therapy, translational research, and regulatory affairs, positioning the company to advance its TCR-T platform toward broader patient access and future combination strategies.Written by Jeffrey Neal JohnsonView Janux Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings ASML (7/16/2025)Bank of America (7/16/2025)The Goldman Sachs Group (7/16/2025)Johnson & Johnson (7/16/2025)Kinder Morgan (7/16/2025)Morgan Stanley (7/16/2025)Progressive (7/16/2025)Prologis (7/16/2025)The PNC Financial Services Group (7/16/2025)Cintas (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
